RT Journal Article
SR Electronic
T1 Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 47
OP 50
VO 112
IS 13
A1 W. T. Hughes
A1 S. Feldman
A1 S. K. Sanyal
YR 1975
UL http://www.cmaj.ca/content/112/13/47.abstract
AB Pneumocystis carinii pneumonitis (PCP) is fatal in 90 to 100% of the cases if no treatment is given. Trimethoprim-sulfamethoxazole (TMP-SMX) was used at one of two dosage levels in the treatment of 20 children with PCP and cancer. Of 14 patients treated with 20 mg TMP--100 mg SMX/kgd, 12 recovered and 2 died. Treatment of the fatal cases and one of the patients who recovered was supplemented with pentamidine. When six patients were treated with 4 to 7 mg TMP--20 to 35 mg SMX/kgd, four recovered and two died. Both fatal cases and one of the patients who recovered were also treated with pentamidine. There was no significant adverse effects from TMP-SMX.